CN1688601A - 活化t细胞核因子受体 - Google Patents

活化t细胞核因子受体 Download PDF

Info

Publication number
CN1688601A
CN1688601A CNA038221330A CN03822133A CN1688601A CN 1688601 A CN1688601 A CN 1688601A CN A038221330 A CNA038221330 A CN A038221330A CN 03822133 A CN03822133 A CN 03822133A CN 1688601 A CN1688601 A CN 1688601A
Authority
CN
China
Prior art keywords
nfat
receptor
antibody
activating
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038221330A
Other languages
English (en)
Chinese (zh)
Inventor
姚正彬
胡光辉
李康
杨建华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of CN1688601A publication Critical patent/CN1688601A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
CNA038221330A 2002-09-19 2003-09-19 活化t细胞核因子受体 Pending CN1688601A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41215702P 2002-09-19 2002-09-19
US60/412,157 2002-09-19

Publications (1)

Publication Number Publication Date
CN1688601A true CN1688601A (zh) 2005-10-26

Family

ID=32030815

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038221330A Pending CN1688601A (zh) 2002-09-19 2003-09-19 活化t细胞核因子受体

Country Status (8)

Country Link
US (4) US20060292668A1 (enExample)
EP (1) EP1562980A4 (enExample)
JP (1) JP2006500032A (enExample)
CN (1) CN1688601A (enExample)
AU (1) AU2003287008A1 (enExample)
CA (1) CA2497937A1 (enExample)
MX (1) MXPA05002818A (enExample)
WO (1) WO2004027079A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197570A1 (zh) * 2015-06-12 2016-12-15 北京艺妙神州医疗科技有限公司 嵌合抗原受体修饰的t细胞及其用途
CN106519005A (zh) * 2016-11-14 2017-03-22 深圳大学 磷酸化nfat3突变体及其应用
CN111454952A (zh) * 2020-04-14 2020-07-28 台州市立医院 一种可抑制nfat基因的靶序列的筛选方法及其应用
CN113533737A (zh) * 2020-04-14 2021-10-22 中国医学科学院药物研究所 Nfam1在筛选防治冠心病药物或制备试剂盒中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329636B2 (es) 2006-02-17 2010-07-26 Universitat De Valencia, Estudi General (Participa Con El 70%) Uso del factor pedf para inducir la auto-renovacion de celulas madre.
US10573722B2 (en) * 2016-02-17 2020-02-25 General Electric Company Systems and methods for in-situ doped semiconductor gate electrodes for wide bandgap semiconductor power devices

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837840A (en) * 1993-09-20 1998-11-17 Board Of Trustees Of Leland Stanford Jr. University NF-AT polypeptides and polynucleotides
US6352830B1 (en) * 1991-08-22 2002-03-05 The Board Of Trustees Of The Leland Stanford Junior University NF-AT polypeptides and polynucleotides and screening methods for immunosuppressive agents
US6197925B1 (en) * 1991-08-22 2001-03-06 Sara Lee Corporation NF-AT polypeptides and polynucleotides
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2002028999A2 (en) * 2000-10-03 2002-04-11 Gene Logic, Inc. Gene expression profiles in granulocytic cells
WO2003016506A2 (en) * 2001-08-17 2003-02-27 Incyte Genomics, Inc. Secreted proteins

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197570A1 (zh) * 2015-06-12 2016-12-15 北京艺妙神州医疗科技有限公司 嵌合抗原受体修饰的t细胞及其用途
CN106519005A (zh) * 2016-11-14 2017-03-22 深圳大学 磷酸化nfat3突变体及其应用
CN106519005B (zh) * 2016-11-14 2019-12-24 深圳大学 磷酸化nfat3突变体及其应用
CN111454952A (zh) * 2020-04-14 2020-07-28 台州市立医院 一种可抑制nfat基因的靶序列的筛选方法及其应用
CN113533737A (zh) * 2020-04-14 2021-10-22 中国医学科学院药物研究所 Nfam1在筛选防治冠心病药物或制备试剂盒中的应用

Also Published As

Publication number Publication date
EP1562980A4 (en) 2006-01-11
MXPA05002818A (es) 2005-08-16
US20100173383A1 (en) 2010-07-08
AU2003287008A1 (en) 2004-04-08
US20110124081A1 (en) 2011-05-26
WO2004027079A2 (en) 2004-04-01
WO2004027079A3 (en) 2005-06-23
US20090022710A1 (en) 2009-01-22
EP1562980A2 (en) 2005-08-17
JP2006500032A (ja) 2006-01-05
CA2497937A1 (en) 2004-04-01
US20060292668A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
CN1665840A (zh) 含有免疫球蛋白结构域的细胞表面识别分子
US20110124081A1 (en) Nuclear factor of activated t cells receptor
CN1254377A (zh) 哺乳动物chk1效应物细胞周期关卡蛋白激酶材料与方法
CN1649897A (zh) Falp蛋白
CN1310758A (zh) 基因克隆的新方法
HK1083631A (en) Nuclear factor of activated t cells receptor
CN1638799A (zh) 人类肥大细胞表达的膜蛋白
CN101039956A (zh) 细胞表面糖蛋白
CN1194012C (zh) 精子生成相关蛋白、其编码序列及用途
CN1491281A (zh) 神经调节素及其应用
CN1352108A (zh) 一种新的多肽——人蝎子短链毒素蛋白18.59和编码这种多肽的多核苷酸
HK1076026A (en) Human mast cell-expressed membrane proteins
CN1273485C (zh) 新型人树突状细胞来源的免疫球蛋白样受体，其编码序列及用途
CN1549857A (zh) 睾丸肉碱转运蛋白及其基因
CN1680438A (zh) 一种人Pif1基因、其编码蛋白及其应用
CN1631898A (zh) 人骨髓基质细胞来源的线粒体转运蛋白分子及其编码序列和用途
CN1342664A (zh) 一种新的多肽——含WD重复域的G－beta蛋白14.08和编码这种多肽的多核苷酸
JP2006204243A (ja) 新規樹状細胞膜分子及びそれをコードするｄｎａ
CN1948490A (zh) 人hRAB－14基因序列、其编码蛋白及制备方法
HK1093916A (en) Human mast cell-expressed membrane protein
CN1718729A (zh) 新型人免疫细胞抑制性受体klrl1的功能及用途
CN1566149A (zh) 树突状细胞来源的免疫抑制性受体，其编码序列及用途
CN1345756A (zh) 一种新的多肽——同边缘系统相联系的膜蛋白(lamp)36.85和编码这种多肽的多核苷酸
CN1920026A (zh) 人hMnk2基因序列、其编码蛋白及制备方法
CN1337405A (zh) 钠离子推动的氯离子/碳酸氢根交换蛋白

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1083631

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20051026

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1083631

Country of ref document: HK